Two rising biotech stocks. One clear long-term winner.
News & Analysis: Vertex Pharmaceuticals
This biotech checks off the two most important criteria that the greatest stocks have.
The biotech's cystic fibrosis treatment potential is far from over.
Which of these top biotech stocks is the more attractive long-term buy?
Vertex started off 2019 on a positive note. But even better days are almost certainly on the way.
VRTX earnings call for the period ending March 31, 2019.
The future looks incredibly bright for these three businesses.
Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.
Looking for potential winning biotech stocks? These five check off all the boxes for investors.
The sky is the limit for this biotech leader.